1. Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate
- Author
-
Zhaobing Gao, Haiyan Xu, Fajun Nan, Fei Chen, Xiaoping Pi, Fu-Yun Tian, Yangming Zhang, Haining Hu, Huanan Liu, Jie Liu, and Li Zhan
- Subjects
medicine.medical_treatment ,Drug Evaluation, Preclinical ,Phenylenediamines ,Pharmacology ,01 natural sciences ,Rats, Sprague-Dawley ,Mice ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Dogs ,Drug Stability ,Seizures ,In vivo ,Drug Discovery ,medicine ,Animals ,Humans ,Protein Isoforms ,Potency ,Structure–activity relationship ,030304 developmental biology ,Electroshock ,0303 health sciences ,KCNQ Potassium Channels ,Chemistry ,Retigabine ,Rats ,0104 chemical sciences ,Disease Models, Animal ,010404 medicinal & biomolecular chemistry ,Anticonvulsant ,Drug Design ,Propargyl ,Molecular Medicine ,Anticonvulsants ,Chemical stability ,Carbamates ,Linker ,Half-Life - Abstract
We previously reported that P-retigabine (P-RTG), a retigabine (RTG) analogue bearing a propargyl group at the nitrogen atom in the linker of RTG, displayed moderate anticonvulsant efficacy. Recently, our further efforts led to the discovery of HN37 (pynegabine), which demonstrated satisfactory chemical stability upon deleting the ortho liable -NH2 group and installing two adjacent methyl groups to the carbamate motif. HN37 exhibited enhanced activation potency toward neuronal Kv7 channels and high in vivo efficacy in a range of pre-clinical seizure models, including the maximal electroshock test and a 6 Hz model of pharmacoresistant limbic seizures. With its improved chemical stability, strong efficacy, and better safety margin, HN37 has progressed to clinical trial in China for epilepsy treatment.
- Published
- 2021